Enzymes

Global Industrial Enzymes Market (2020 to 2027) - Featuring BASF, Novozymes and DSM Among Others - ResearchAndMarkets.com

Retrieved on: 
星期三, 八月 4, 2021
Engineering, Chemicals, Plastics, Manufacturing, Proteins, Chemistry, Enzymes, Physical sciences, Catalysis, Hydrolases, Lipase, Industrial enzymes, Cellulase, Enzyme, Biotechnology, Cross-linked enzyme aggregate

Further, the market for industrial enzymes is continuously rising, owing to the growing need for sustainable solutions.

Key Points: 
  • Further, the market for industrial enzymes is continuously rising, owing to the growing need for sustainable solutions.
  • Advancement in biotechnology, especially in protein engineering, has also brought in new probiotic products, driving the industrial enzymes market to the next level.
  • Carbohydrases, Amylases, Cellulases, Proteases and Lipases are major variants existing in the global Enzymes Market.
  • Additionally, expanding investment in the food and beverage and pharmaceutical industry is anticipated to stimulate the overall industrial enzymes market.

Health Holland Awards Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals

Retrieved on: 
星期一, 八月 2, 2021
DNA replication, Enzymes, Branches of biology, Macromolecules, Molecules, Drug resistance, DNA polymerase II, DNA polymerase I

Dr. Smits stated: "This collaborative grant opportunity will be a novel scientific accomplishment contributing to Acurx programs by enhancing knowledge of the structure of pol IIIC from different pathogenic, multidrug-resistant organisms.

Key Points: 
  • Dr. Smits stated: "This collaborative grant opportunity will be a novel scientific accomplishment contributing to Acurx programs by enhancing knowledge of the structure of pol IIIC from different pathogenic, multidrug-resistant organisms.
  • Additionally, we will study the binding of Acurx drug candidates in complex with pol IIIC enzymes to establish a detailed in vitro characterization of polymerase and inhibiting activity."
  • These results have validated the therapeutic effect of DNA pol IIIC as a bacterial target.
  • Leiden University Medical Center (LUMC) research aims to meet the highest international standards of quality and academic integrity.

Editas Medicine and IDT Announce Publication in Nature Communications of Research Data Supporting the Use of Optimized AsCas12a Nuclease Variant, Alt-R A.s. Cas12a (Cpf1) Ultra, in Researching the Potential of Gene-Edited Cell Medicines

Retrieved on: 
星期四, 七月 29, 2021
Branches of biology, Genetic engineering, Biology, Enzymes, Life sciences, Genome editing, Biotechnology, Molecular biology, CRISPR, Cpf1, Nuclease, IDT

We believe this proprietary nuclease could have important applications in the development of novel therapies for serious genetic diseases such as sickle cell disease.

Key Points: 
  • We believe this proprietary nuclease could have important applications in the development of novel therapies for serious genetic diseases such as sickle cell disease.
  • Overall, the results support further research for the use of Alt-R A.s. Cas12a (Cpf1) Ultra as an advanced CRISPR nuclease with significant potential future applications.
  • Through its GMP services, IDT manufactures products used by scientists researching many forms of cancer and most inherited and infectious diseases.
  • IDT is widely recognized as the industry leader in custom nucleic acid manufacture, serving over 130,000 life sciences researchers.

M6P Therapeutics Presented Data on M041, A Recombinant Enzyme Therapy, for the Treatment of Sanfilippo B Syndrome at MPS 2021

Retrieved on: 
星期三, 七月 28, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical trials, Enzymes, Branches of biology, NAGLU, Alpha-N-acetylglucosaminidase, Lysosomal storage disease, Glucocerebrosidase, Mannose 6-phosphate, Mannose, Lysosome, Glycoside hydrolase family 89, Mucopolysaccharidosis, Sanfilippo B Syndrome, M6P Therapeutics, SANFILIPPO B SYNDROME, M6P THERAPEUTICS

These data illustrate M041s potential as a recombinant enzyme therapy utilizing a recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) with improved mannose 6-phosphorylation.

Key Points: 
  • These data illustrate M041s potential as a recombinant enzyme therapy utilizing a recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) with improved mannose 6-phosphorylation.
  • There are currently no approved therapies for Sanfilippo B syndrome, also known as MPS IIIB.
  • Sanfilippo B syndrome is characterized by a defect in the NAGLU gene providing instructions for producing the enzyme alpha-N-acetylglucosaminidase.
  • M6P Therapeutics is a privately held, venture-backed biotechnology company developing the next-generation of targeted recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs).

HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS® in Patients with MET Amplified Gastric Cancer

Retrieved on: 
星期三, 七月 28, 2021
Enzymes, Tyrosine kinase receptors, Companies, Tyrosine kinase inhibitor, AstraZeneca, Tyrosine kinase, C-Met, TKI, Quinazolines, Pyrrolidines

Patients whose tumors harbor MET amplification were treated with ORPATHYS monotherapy, reporting an ORR of 50% (10/20, 95% CI: 28.0, 71.9).

Key Points: 
  • Patients whose tumors harbor MET amplification were treated with ORPATHYS monotherapy, reporting an ORR of 50% (10/20, 95% CI: 28.0, 71.9).
  • ORPATHYS is an oral, potent, and highly selective MET tyrosine kinase inhibitor (TKI) that has demonstrated clinical activity in advanced solid tumors.
  • In 2011, following its discovery and initial development by HUTCHMED, AstraZeneca and HUTCHMED entered a global licensing agreement to jointly develop and commercialize ORPATHYS.
  • Joint development in China is led by HUTCHMED, while AstraZeneca leads development outside of China.

Ultragenyx Receives Orphan Drug Designation from FDA and European Commission for UX053, an Investigational mRNA-therapy for the Treatment of Glycogen Storage Disease Type III

Retrieved on: 
星期二, 七月 27, 2021
Hepatology, Enzymes, Inborn errors of carbohydrate metabolism, Medical specialties, Branches of biology, Glycogen storage disease type III, Glycogen storage disease, Glycogen debranching enzyme, Orphan drug, Debranching enzyme, Glycogen, AGL

The FDA Orphan Drug Designation program provides orphan status to drugs and biologics that are intended for the safe and effective treatment, diagnosis, or prevention of rare diseases that affect fewer than 200,000 people in the U.S.

Key Points: 
  • The FDA Orphan Drug Designation program provides orphan status to drugs and biologics that are intended for the safe and effective treatment, diagnosis, or prevention of rare diseases that affect fewer than 200,000 people in the U.S.
  • Among the benefits of orphan designation in the U.S. are seven years of market exclusivity following FDA approval, waiver or partial payment of application fees, and tax credits for clinical testing expenses conducted after orphan designation is received.
  • Glycogen Storage Disease Type III, or GSDIII, a disease caused by a glycogen debranching enzyme (AGL) deficiency that results in glycogen accumulation in the liver and muscle.
  • The company is led by a management team experienced in the development and commercialization of rare disease therapeutics.

BridgeBio Announces Clinical Collaboration with Bristol Myers Squibb to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with OPDIVO® (nivolumab) in Advanced Solid Tumors with KRAS Mutations

Retrieved on: 
星期二, 七月 27, 2021
Enzymes, Branches of biology, Signal transduction, Mitogen-activated protein kinase, Ras GTPase, PTPN11, Programmed cell death protein 1, Nivolumab, IRS1, MAPK/ERK pathway

Under the terms of the non-exclusive collaboration, BridgeBio will sponsor the study and Bristol Myers Squibb will provide nivolumab.

Key Points: 
  • Under the terms of the non-exclusive collaboration, BridgeBio will sponsor the study and Bristol Myers Squibb will provide nivolumab.
  • Both BridgeBio and Bristol Myers Squibb will share the cost of clinical development activities for the combination trial.
  • SHP2 is a protein-tyrosine phosphatase that links growth factor, cytokine and integrin signaling with the downstream RAS/ERK MAPK pathway to regulate cellular proliferation and survival.
  • Combination of anti-PD-1 treatment with BBP-398, and other targeted therapies, could be promising for patients with KRAS mutations.

ChromaDex to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021

Retrieved on: 
星期二, 七月 20, 2021
Biotechnology, Pharmaceutical, Health, Enzymes, ChromaDex, Nicotinamide riboside, Nucleotides, B vitamins, Nicotinamide adenine dinucleotide, Nicotinamide, NAD, Elysium Health

ChromaDex Corp. is a global bioscience company dedicated to healthy aging.

Key Points: 
  • ChromaDex Corp. is a global bioscience company dedicated to healthy aging.
  • The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age.
  • ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen.
  • ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

FibroGen Announces Outcome of FDA Advisory Committee Review of Roxadustat for Treatment of Anemia of Chronic Kidney Disease

Retrieved on: 
星期四, 七月 15, 2021
Enzymes, Chemical compounds, Acetic acids, Organic compounds, Isoquinolines, Roxadustat, Hypoxia-inducible factor, Anemias, Myelodysplastic syndrome, HIF prolyl-hydroxylase inhibitor, Procollagen-proline dioxygenase, Chronic kidney disease

Roxadustat, an oral small molecule hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, is the first HIF-PH inhibitor accepted by the FDA for review for the treatment of anemia of CKD.

Key Points: 
  • Roxadustat, an oral small molecule hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, is the first HIF-PH inhibitor accepted by the FDA for review for the treatment of anemia of CKD.
  • Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA).
  • The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia of chronic kidney disease (CKD).
  • Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA).

Codexis Announces Completion of CodeEvolver® License Technology Transfer with Global Pharmaceutical Leader

Retrieved on: 
星期三, 七月 14, 2021
Life sciences, Natural sciences, Biology, Codexis, Catalysis, Enzymes, Biomolecules, Metabolism, Process chemicals, Novartis, Enzyme, Protein engineering

In May 2019, the two companies signed a platform technology transfer and license agreement, under which Novartis has a non-exclusive license to CodeEvolver to develop novel performance enzymes for use in the manufacture of pharmaceutical products.

Key Points: 
  • In May 2019, the two companies signed a platform technology transfer and license agreement, under which Novartis has a non-exclusive license to CodeEvolver to develop novel performance enzymes for use in the manufacture of pharmaceutical products.
  • We are pleased to have completed the CodeEvolver installation for Novartis, enabling our long-time customer to leverage Codexis proprietary enzyme engineering technology, said Stefan Lutz, Senior Vice President of Research of Codexis.
  • Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver platform to discover and develop novel, high performance enzymes and novel biotherapeutics.
  • Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.